Figure 1. Orlistat increases the therapeutic effects of enzalutamide on PC3 cells.

(A) A total of 5 × 10³ PC3 cells/well were seeded into a 96-well plate. The next day, cells were treated with different doses of orlistat alone, enzalutamide alone and a combination of orlistat plus enzalutamide for 48 h. The cell viabilities were evaluated with an AlamarBlue assay. The calculated IC₅₀ of orlistat alone, enzalutamide alone and combination treatment (COMB) were 80, 100 and 35 µM, respectively, in PC3 cells. (B) Quantification of (A). All experiments were repeated at least three times. ***P<0.001 vs. orlistat alone. ^$P<0.05 and ^$$$P<0.001 vs. combination and enzalutamide alone.